NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

生物防禦市場全球市場:2021年∼2025年

Global Biodefense Market 2021-2025

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 1023643
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
生物防禦市場全球市場:2021年∼2025年 Global Biodefense Market 2021-2025
出版日期: 2021年06月15日內容資訊: 英文 120 Pages
簡介

全球生物防禦市場市場規模在2021年∼2025年間,預測將成長到增長54億1萬美元,在預測期間中預計將以7%的年複合成長率增長。

市場成長的主要因素有感染疾病的流行擴大,政府研究開發費的劇增。

本報告涵括生物防禦市場全球市場的整體分析,提供市場規模與預測,趨勢,成長要素,課題,及約25供應商的分析。

目錄

摘要整理

市場形勢

  • 市場生態系統
  • 價值鏈分析

市場規模

  • 市場定義
  • 市場區隔分析
  • 2020年的市場規模
  • 市場預測:從2020年∼2025年的預測

波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入廠商業者的威脅
  • 替代品的威脅
  • 競爭的威脅
  • 市場情況

市場區隔:各應用領域

  • 市場區隔
  • 各應用領域比較
  • 炭疽菌:市場規模與預測(2020年∼2025年)
  • 天花:市場規模與預測(2020年∼2025年)
  • 肉毒桿菌中毒:市場規模與預測(2020年∼2025年)
  • 其他:市場規模與預測(2020年∼2025年)
  • 各應用領域的市場機會

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美:市場規模與預測(2020年∼2025年)
  • 歐洲:市場規模與預測(2020年∼2025年)
  • 亞洲:市場規模與預測(2020年∼2025年)
  • 其他地區:市場規模與預測(2020年∼2025年)
  • 主要國家
  • 各地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Alexeter Technologies LLC
  • Alnylam Pharmaceuticals Inc.
  • Altimmune Inc.
  • ANP Technologies Inc.
  • Bavarian Nordic AS
  • Cleveland BioLabs Inc.
  • Elusys Therapeutics Inc.
  • Emergent BioSolutions Inc.
  • General Dynamics Corp.
  • GlaxoSmithKline Plc

附錄

目錄
Product Code: IRTNTR43768

Technavio has been monitoring the biodefense market and it is poised to grow by $ 5.41 bn during 2021-2025, progressing at a CAGR of over 7% during the forecast period. Our report on the biodefense market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of infectious diseases and rapid increase in government funding in R&D. In addition, the rising prevalence of infectious diseases is anticipated to boost the growth of the market as well.

The biodefense market analysis includes the application segment and geographic landscape.

Technavio's biodefense market is segmented as below:

By Application

  • Anthrax
  • Smallpox
  • Botulism
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing threat of bioterrorism as one of the prime reasons driving the biodefense market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on biodefense market covers the following areas:

  • Biodefense market sizing
  • Biodefense market forecast
  • Biodefense market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biodefense market vendors that include Alexeter Technologies LLC, Alnylam Pharmaceuticals Inc., Altimmune Inc., ANP Technologies Inc., Bavarian Nordic AS, Cleveland BioLabs Inc., Elusys Therapeutics Inc., Emergent BioSolutions Inc., General Dynamics Corp., and GlaxoSmithKline Plc. Also, the biodefense market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Application
    • Market segments
    • Comparison by Application
    • Anthrax - Market size and forecast 2020-2025
    • Smallpox - Market size and forecast 2020-2025
    • Botulism - Market size and forecast 2020-2025
    • Others - Market size and forecast 2020-2025
    • Market opportunity by Application
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity By Geographical Landscape
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Vendor landscape
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Alexeter Technologies LLC
    • Alnylam Pharmaceuticals Inc.
    • Altimmune Inc.
    • ANP Technologies Inc.
    • Bavarian Nordic AS
    • Cleveland BioLabs Inc.
    • Elusys Therapeutics Inc.
    • Emergent BioSolutions Inc.
    • General Dynamics Corp.
    • GlaxoSmithKline Plc
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations
  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Application - Market share 2020-2025 (%)
  • 22: Comparison by Application
  • 23: Anthrax - Market size and forecast 2020-2025 ($ million)
  • 24: Anthrax - Year-over-year growth 2020-2025 (%)
  • 25: Smallpox - Market size and forecast 2020-2025 ($ million)
  • 26: Smallpox - Year-over-year growth 2020-2025 (%)
  • 27: Botulism - Market size and forecast 2020-2025 ($ million)
  • 28: Botulism - Year-over-year growth 2020-2025 (%)
  • 29: Others - Market size and forecast 2020-2025 ($ million)
  • 30: Others - Year-over-year growth 2020-2025 (%)
  • 31: Market opportunity by Application
  • 32: Customer landscape
  • 33: Market share By Geographical Landscape 2020-2025 (%)
  • 34: Geographic comparison
  • 35: North America - Market size and forecast 2020-2025 ($ million)
  • 36: North America - Year-over-year growth 2020-2025 (%)
  • 37: Europe - Market size and forecast 2020-2025 ($ million)
  • 38: Europe - Year-over-year growth 2020-2025 (%)
  • 39: Asia - Market size and forecast 2020-2025 ($ million)
  • 40: Asia - Year-over-year growth 2020-2025 (%)
  • 41: ROW - Market size and forecast 2020-2025 ($ million)
  • 42: ROW - Year-over-year growth 2020-2025 (%)
  • 43: Key leading countries
  • 44: Market opportunity By Geographical Landscape ($ million)
  • 45: Impact of drivers and challenges
  • 46: Vendor landscape
  • 47: Landscape disruption
  • 48: Industry risks
  • 49: Vendors covered
  • 50: Market positioning of vendors
  • 51: Alexeter Technologies LLC - Overview
  • 52: Alexeter Technologies LLC - Product and service
  • 53: Alexeter Technologies LLC - Key offerings
  • 54: Alexeter Technologies LLC - Key customers
  • 55: Alexeter Technologies LLC - Segment focus
  • 56: Alnylam Pharmaceuticals Inc. - Overview
  • 57: Alnylam Pharmaceuticals Inc. - Product and service
  • 58: Alnylam Pharmaceuticals Inc. - Key offerings
  • 59: Alnylam Pharmaceuticals Inc. - Key customers
  • 60: Alnylam Pharmaceuticals Inc. - Segment focus
  • 61: Altimmune Inc. - Overview
  • 62: Altimmune Inc. - Business segments
  • 63: Altimmune Inc. - Key offerings
  • 64: Altimmune Inc. - Key customers
  • 65: Altimmune Inc. - Segment focus
  • 66: ANP Technologies Inc. - Overview
  • 67: ANP Technologies Inc. - Product and service
  • 68: ANP Technologies Inc. - Key offerings
  • 69: ANP Technologies Inc. - Key customers
  • 70: ANP Technologies Inc. - Segment focus
  • 71: Bavarian Nordic AS - Overview
  • 72: Bavarian Nordic AS - Product and service
  • 73: Bavarian Nordic AS - Key offerings
  • 74: Bavarian Nordic AS - Key customers
  • 75: Bavarian Nordic AS - Segment focus
  • 76: Cleveland BioLabs Inc. - Overview
  • 77: Cleveland BioLabs Inc. - Product and service
  • 78: Cleveland BioLabs Inc. - Key offerings
  • 79: Cleveland BioLabs Inc. - Key customers
  • 80: Cleveland BioLabs Inc. - Segment focus
  • 81: Elusys Therapeutics Inc. - Overview
  • 82: Elusys Therapeutics Inc. - Product and service
  • 83: Elusys Therapeutics Inc. - Key offerings
  • 84: Elusys Therapeutics Inc. - Key customers
  • 85: Elusys Therapeutics Inc. - Segment focus
  • 86: Emergent BioSolutions Inc. - Overview
  • 87: Emergent BioSolutions Inc. - Business segments
  • 88: Emergent BioSolutions Inc. - Key offerings
  • 89: Emergent BioSolutions Inc. - Key customers
  • 90: Emergent BioSolutions Inc. - Segment focus
  • 91: General Dynamics Corp. - Overview
  • 92: General Dynamics Corp. - Business segments
  • 93: General Dynamics Corp. - Key offerings
  • 94: General Dynamics Corp. - Key customers
  • 95: General Dynamics Corp. - Segment focus
  • 96: GlaxoSmithKline Plc - Overview
  • 97: GlaxoSmithKline Plc - Business segments
  • 98: GlaxoSmithKline Plc - Key offerings
  • 99: GlaxoSmithKline Plc - Key customers
  • 100: GlaxoSmithKline Plc - Segment focus
  • 101: Currency conversion rates for US$
  • 102: Research Methodology
  • 103: Validation techniques employed for market sizing
  • 104: Information sources
  • 105: List of abbreviations